Nuvation Bio Inc Ordinary Shares - Class A NUVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
-
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
-
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
-
Nuvation Bio Shares Sink Premarket With Plans for Convertible Notes Offering
-
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
-
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
-
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
-
Nuvation Bio Collaborates With Thermo Fisher Scientific For Lung Cancer Treatment
Trading Information
- Previous Close Price
- $5.90
- Day Range
- $5.61–5.88
- 52-Week Range
- $2.18–9.75
- Bid/Ask
- $5.60 / $5.69
- Shares Outstanding
- 348.20M
- Market Cap
- $1.96B
- Volume/Avg
- 4M / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.49
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 307
- Website
- https://www.nuvationbio.com
Valuation
|
Metric
|
NUVB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.42 |
Price/Sales | 14.49 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NUVB
|
|---|---|
Quick Ratio | 7.04 |
Current Ratio | 7.44 |
Interest Coverage | −7.22 |
Quick Ratio
NUVB
Profitability
|
Metric
|
NUVB
|
|---|---|
Return on Assets (Normalized) | −19.19% |
Return on Equity (Normalized) | −32.42% |
Return on Invested Capital (Normalized) | −28.70% |
Return on Assets
NUVB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#>R?fW | LOCK|J>?B? | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%%C$B%v | LOCK|NDSQN | $70B | |||
| argenx SE ADR
ARGX
| LOCK|@#s<&BM | LOCK|m%H | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>HP@##q | LOCK|<L&St | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Q?NZg! | LOCK|>g | $37B | |||
| Moderna Inc
MRNA
| LOCK|@D#<wg> | LOCK|F$l | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|q>s@%%Wr | LOCK|MwNt | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|#^^C?&T | LOCK|<Pq | $23B | |||
| Incyte Corp
INCY
| LOCK|@Hr&&V | LOCK|cD | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$fg$d%S | LOCK|%lD | $16B |
United States